USS Investment Management Ltd Purchases 13,263 Shares of Abbott Laboratories $ABT

USS Investment Management Ltd raised its position in shares of Abbott Laboratories (NYSE:ABT) by 4.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 303,839 shares of the healthcare product maker’s stock after acquiring an additional 13,263 shares during the period. USS Investment Management Ltd’s holdings in Abbott Laboratories were worth $31,171,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. American National Bank of Texas raised its stake in Abbott Laboratories by 2.4% during the fourth quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after purchasing an additional 79 shares in the last quarter. Nia Impact Advisors LLC grew its stake in shares of Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after buying an additional 79 shares in the last quarter. Park Place Capital Corp increased its holdings in shares of Abbott Laboratories by 11.0% in the 4th quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock worth $102,000 after buying an additional 81 shares during the last quarter. Lantern Wealth Advisors LLC raised its position in shares of Abbott Laboratories by 1.7% during the 3rd quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker’s stock valued at $674,000 after buying an additional 84 shares in the last quarter. Finally, Clayton Financial Group LLC lifted its holdings in shares of Abbott Laboratories by 1.4% in the 4th quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock valued at $779,000 after acquiring an additional 84 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

ABT stock opened at $90.68 on Wednesday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The firm has a market cap of $157.95 billion, a price-to-earnings ratio of 25.40, a PEG ratio of 1.60 and a beta of 0.63. The business’s fifty day simple moving average is $88.91 and its two-hundred day simple moving average is $104.84. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.8%. Abbott Laboratories’s dividend payout ratio is 70.59%.

Analyst Upgrades and Downgrades

Several research firms recently commented on ABT. Leerink Partners dropped their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research report on Tuesday, April 21st. Weiss Ratings lowered Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 16th. Jefferies Financial Group cut their target price on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Raymond James Financial decreased their price target on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Finally, The Goldman Sachs Group lowered their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $118.30.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Wall Street continues to view Abbott as a strong income name, with a TipRanks roundup highlighting ABT as one of three dividend aristocrats currently rated a Strong Buy by analysts. 3 Dividend Aristocrat Stocks Wall Street Loves Right Now — June 30, 2026
• Positive Sentiment: Wells Fargo reiterated its Buy rating on Abbott, reinforcing the view that the stock still has analyst support despite recent volatility. Wells Fargo Remains a Buy on Abbott Laboratories (ABT)
• Positive Sentiment: Abbott’s largest Medical Devices segment is being positioned for a new growth phase, helped by diabetes, heart rhythm, and electrophysiology product momentum. How Abbott’s Largest Segment Is Preparing for the Next Growth Phase
• Neutral Sentiment: News that the U.S. DOJ closed its criminal probe into Abbott’s infant formula plant removes a major legal uncertainty, but reports also say the company is still facing a proposed civil settlement and penalties under the False Claims Act, so the issue is not fully resolved. US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
• Negative Sentiment: Recent market coverage says ABT underperformed in Monday’s session and settled lower, indicating investors were already cautious before the latest news flow. Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.